Komodo Healthcare Map claims data from 08-Oct-2016 to the date of most recent data from patients with wet AMD who initiated brolucizumab were analyzed in this study.~Identification period of the index date (index period): The patients fulfilling the selection criteria were identified during the period from 08-Oct-2019 to 30-Apr-2020.~Index date: Defined as the date of the earliest brolucizumab injection during the index period.~Study Period: The period from 08-Oct-2016 to the most recent data extraction date (05-Jun-2020).~o Note since 05-Jun-2020 was the date data was pulled, claims data from recent months (e.g. May) may be incomplete (relative to the final DB state) as well.~Pre-index period: The period 36 months prior to the index date~o Note: Data within 36 months prior to the index date will be used to assess baseline characteristics.~Post-index period: The period of 180 days after the index date
This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the Komodo Healthcare Map.